By Michael Knox
25 August 2021, 8:30 AM
Chief Economist Michael Knox says the Aussie dollar will move higher. He estimates current fair value is just over 90 US cents, which is 20 cents higher than where it is currently trading.
What does this mean for your investment strategy?
Read more...
By Nick Harris
25 August 2021, 8:00 AM
SLC’s FY21 result was in line with our expectations. On a continuing business basis revenue grew 14% and underlying EBITDA grew 108%
Read more...
By Dr Derek Jellinek
25 August 2021, 7:30 AM
FY21 was in line with guidance, albeit below our expectations, with record organic sales and underlying earnings growth driven via unprecedented PPE demand.
Read more...
By Scott Murdoch
25 August 2021, 7:00 AM
HUB reported in line with expectations: underlying EBITDA A$36.2m and underlying FY21 NPAT A$15m, +49% on pcp.
Read more...
By Andrew Tang
25 August 2021, 6:00 AM
Today, Wednesday the 25th of August, we are happy to buy Ansell (ASX:ANN), HUB24 Ltd (ASX:HUB), Superloop (ASX:SLC), Aerometrex Limited (ASX:AMX), Monash IVF Group Ltd (ASX:MVF), Virtus Health Ltd (ASX:VRT) and Viva Energy Group (ASX:VEA).
Read more...
By Alex Lu
24 August 2021, 10:30 AM
Reliance Worldwide's (ASX:RWC) FY21 result was comfortably above our expectations.
Read more...
By Steven Sassine
24 August 2021, 9:30 AM
Camplify (ASX:CHL) released its FY21 result, with all key headline metrics coming in ahead of prospectus forecasts/recently provided guidance. The NPAT loss of A$2.1m was also better than our estimates.
Read more...
By Dr Derek Jellinek
24 August 2021, 9:00 AM
FY21 underlying results were in line with consensus expectations, albeit above our estimates, with COVID testing driving upside across all laboratory businesses.
Read more...
By Richard Coles
24 August 2021, 8:00 AM
The key result themes, in our view, were largely as expected with a strong ARHI result offsetting some weakness in other divisions (IIHI and travel), although the 2H21 IIHI performance was weaker than expected.
Read more...
By Scott Power
24 August 2021, 7:00 AM
Mach7 Technologies (ASX:M7T) posted an in-line result for FY21. The highlights included a record sales order book and further R&D spend (28% of revenue) into new product development.
Read more...